P. A. Sreeja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
P. A. Sreeja has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ameena Kadar K. A.
Grace College of Pharmacy, India
2 shared publications - Dhanalakshmi Perumal
Department of Pharmacy Practice, Faculty of Pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, India
2 shared publications - V. Karthikeyan
Grace College of Pharmacy, India
2 shared publications - A. M. T. Gurubasavaraj
YSS College of Pharmacy, India
1 shared publication - Adinarayana Andy
Mass General Brigham, USA
1 shared publication - Aiswarya Nair
Madras Medical College, India
1 shared publication
Latest Publications
- 14 December 2026
- Published by IGI Global Scientific Publishing
- p. 437-460
Holistic Management of Vitiligo
The purpose of this chapter, per the authors, is to detail a patient-centered framework for vitiligo management that bridges cutaneous disease control, psychodermatology, interdisciplinary collaboration, and digital health innovations. Vitiligo is framed as a complex systemic disorder requiring evaluation beyond physical repigmentation to address the brain-skin axis, psychiatric comorbidity, and quality of life. This chapter, per the authors, outlines how integrated multidisciplinary teams optimize personalized pharmacotherapy, phototherapy, and behavioral support. Furthermore, this chapter, per the authors, examines precision tools, including artificial intelligence for automated lesion segmentation, tele-dermatology, and multi-omics profiling, while addressing key socio-technical hurdles regarding algorithmic equity and data privacy.
- 14 December 2026
- Published by IGI Global Scientific Publishing
- p. 437-460
Holistic Management of Vitiligo
The purpose of this chapter, per the authors, is to detail a patient-centered framework for vitiligo management that bridges cutaneous disease control, psychodermatology, interdisciplinary collaboration, and digital health innovations. Vitiligo is framed as a complex systemic disorder requiring evaluation beyond physical repigmentation to address the brain-skin axis, psychiatric comorbidity, and quality of life. This chapter, per the authors, outlines how integrated multidisciplinary teams optimize personalized pharmacotherapy, phototherapy, and behavioral support. Furthermore, this chapter, per the authors, examines precision tools, including artificial intelligence for automated lesion segmentation, tele-dermatology, and multi-omics profiling, while addressing key socio-technical hurdles regarding algorithmic equity and data privacy.
- 14 December 2026
- Published by IGI Global Scientific Publishing
- p. 233-258
Combination Therapies and Targeted Immunomodulation in Vitiligo
According to the authors, this chapter offers a thorough summary of current combination treatments and targeted immunomodulation in vitiligo via a precision medicine and AI-augmented lens. The complex immunopathogenesis of the disease, oxidative stress, IFN-γ-driven inflammation, and tissue-resident memory T-cell biology are discussed, along with the reasons why sustained repigmentation is rarely achieved by monotherapy. In addition to JAK inhibitors, cytokine- and chemokine-directed biologics, and surgical-regenerative treatments for stable disease, conventional regimens that combine phototherapy with topicals, antioxidants, and vitamin D analogues are evaluated. AI-driven phenotyping, multi-omics integration, and predictive modeling for customized regimen selection are highlighted. Equity, safety, and ethical issues are evaluated seriously. Future directions, such as biomarker-stratified trials, IL-15-targeted maintenance, drug delivery advances, and explainable AI for reliable clinical decision support, are outlined in the chapter's conclusion.
- 14 December 2026
- Published by IGI Global Scientific Publishing
- p. 233-258
Combination Therapies and Targeted Immunomodulation in Vitiligo
According to the authors, this chapter offers a thorough summary of current combination treatments and targeted immunomodulation in vitiligo via a precision medicine and AI-augmented lens. The complex immunopathogenesis of the disease, oxidative stress, IFN-γ-driven inflammation, and tissue-resident memory T-cell biology are discussed, along with the reasons why sustained repigmentation is rarely achieved by monotherapy. In addition to JAK inhibitors, cytokine- and chemokine-directed biologics, and surgical-regenerative treatments for stable disease, conventional regimens that combine phototherapy with topicals, antioxidants, and vitamin D analogues are evaluated. AI-driven phenotyping, multi-omics integration, and predictive modeling for customized regimen selection are highlighted. Equity, safety, and ethical issues are evaluated seriously. Future directions, such as biomarker-stratified trials, IL-15-targeted maintenance, drug delivery advances, and explainable AI for reliable clinical decision support, are outlined in the chapter's conclusion.
- 14 August 2026
- Published by IGI Global Scientific Publishing
- p. 379-406
AI-Based Safety, Explainability, and Risk Assessment in Gene and Cell Therapies
AI is ushering in a significant paradigm shift across gene and cell therapies (G&CTs), advancing the field away from conventional, trial-and-error treatments toward precision molecular corrections. Although could treat a wide variety of diseases, these complex, living therapeutics raise enormous safety and manufacturing concerns such as genotoxicity, insertional mutagenesis, immunogenicity and extreme batch-to-batch heterogeneity. To address the high-stakes clinical translation while promoting safety, you must dismantle the “black-box” dilemma by utilizing Explainable AI (XAI) frameworks such as SHAP and LIME or glass-box based modeling to ensure biological traceability and regulatory compliance. Even more, AI maximizes biomanufacturing through real-time Process Analytical Technology (PAT), unsupervised anomaly detection, and predictive cold-chain logistics. In order to deploy these algorithmic tools successfully, we need validation protocols with continuous monitoring for model drift; inclusive multi-ethnic datasets to eliminate systemic bias; and adaptive regulatory mechanisms.
- 14 August 2026
- Published by IGI Global Scientific Publishing
- p. 379-406
AI-Based Safety, Explainability, and Risk Assessment in Gene and Cell Therapies
AI is ushering in a significant paradigm shift across gene and cell therapies (G&CTs), advancing the field away from conventional, trial-and-error treatments toward precision molecular corrections. Although could treat a wide variety of diseases, these complex, living therapeutics raise enormous safety and manufacturing concerns such as genotoxicity, insertional mutagenesis, immunogenicity and extreme batch-to-batch heterogeneity. To address the high-stakes clinical translation while promoting safety, you must dismantle the “black-box” dilemma by utilizing Explainable AI (XAI) frameworks such as SHAP and LIME or glass-box based modeling to ensure biological traceability and regulatory compliance. Even more, AI maximizes biomanufacturing through real-time Process Analytical Technology (PAT), unsupervised anomaly detection, and predictive cold-chain logistics. In order to deploy these algorithmic tools successfully, we need validation protocols with continuous monitoring for model drift; inclusive multi-ethnic datasets to eliminate systemic bias; and adaptive regulatory mechanisms.
- 14 August 2026
- Published by IGI Global Scientific Publishing
- p. 351-378
Clinical Implementation of AI-Driven Gene and Cell Therapies
The clinical translation of artificial intelligence-driven gene and cell therapies extends well beyond regulatory approval, depending on certified treatment-center infrastructure, integrated health workflows, and durable post-market evidence programs. This chapter, per the authors, examines how artificial intelligence tools are reshaping clinical implementation across four therapeutic platforms: CD19-directed CAR-T therapy in diffuse large B-cell lymphoma, AAV-based gene therapy in hemophilia, CRISPR-Cas9 editing in sickle cell disease and beta-thalassemia, and tumor-infiltrating lymphocyte therapy in metastatic melanoma. Grounded in recent quantitative real-world evidence, the text outlines a five-domain operational framework for AI-capable treatment sites. Additionally, it addresses the equity and global access challenges that will shape the field over the next decade, identifying persistent infrastructure, financing, and long-term follow-up obligations as defining operational themes.
- 14 August 2026
- Published by IGI Global Scientific Publishing
- p. 351-378
Clinical Implementation of AI-Driven Gene and Cell Therapies
The clinical translation of artificial intelligence-driven gene and cell therapies extends well beyond regulatory approval, depending on certified treatment-center infrastructure, integrated health workflows, and durable post-market evidence programs. This chapter, per the authors, examines how artificial intelligence tools are reshaping clinical implementation across four therapeutic platforms: CD19-directed CAR-T therapy in diffuse large B-cell lymphoma, AAV-based gene therapy in hemophilia, CRISPR-Cas9 editing in sickle cell disease and beta-thalassemia, and tumor-infiltrating lymphocyte therapy in metastatic melanoma. Grounded in recent quantitative real-world evidence, the text outlines a five-domain operational framework for AI-capable treatment sites. Additionally, it addresses the equity and global access challenges that will shape the field over the next decade, identifying persistent infrastructure, financing, and long-term follow-up obligations as defining operational themes.
- Open Access
- 23 January 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23 (1) , 70
Navigating hypertensive disorders in pregnancy: a systematic review
- 23 January 2026
- Published by Springer Nature in Discover Public Health
- Vol. 23 (1) , 70
Open AccessNavigating hypertensive disorders in pregnancy: a systematic review
- 20 November 2025
- Published by IGI Global Scientific Publishing
- p. 79-106
Amazon Ethnomedicine and Malaria Control in Latin America, Field Based Plant Surveys and Partnership With Indigenous Communities
Malaria persists across the Amazon basin as ecological conditions, deforestation, mobility, and health system gaps sustain transmission in indigenous and riverine communities. This chapter examines ethnomedicine as a complementary pathway for malaria control in Latin America, positioning traditional knowledge within epidemiological, ecological, and political realities. It details participatory, field-based plant surveys semi-structured interviews, guided walks, herbarium validation, and access-and-benefit-sharing to document medicinal plants and link community pharmacopeias to phytochemical profiling and in vitro antiplasmodial testing. Case studies show therapeutic promise, toxicity cautions, and polyherbal synergy. The chapter advances intercultural health models linking traditional healers, community health agents, rapid diagnostics, and conservation-linked medicinal gardens, and proposes policy paths for recognition of indigenous health systems, sustainable harvesting, equitable benefit-sharing, and governance aligning biodiversity stewardship with resilient malaria control.
- 20 November 2025
- Published by IGI Global Scientific Publishing
- p. 79-106
Amazon Ethnomedicine and Malaria Control in Latin America, Field Based Plant Surveys and Partnership With Indigenous Communities
Malaria persists across the Amazon basin as ecological conditions, deforestation, mobility, and health system gaps sustain transmission in indigenous and riverine communities. This chapter examines ethnomedicine as a complementary pathway for malaria control in Latin America, positioning traditional knowledge within epidemiological, ecological, and political realities. It details participatory, field-based plant surveys semi-structured interviews, guided walks, herbarium validation, and access-and-benefit-sharing to document medicinal plants and link community pharmacopeias to phytochemical profiling and in vitro antiplasmodial testing. Case studies show therapeutic promise, toxicity cautions, and polyherbal synergy. The chapter advances intercultural health models linking traditional healers, community health agents, rapid diagnostics, and conservation-linked medicinal gardens, and proposes policy paths for recognition of indigenous health systems, sustainable harvesting, equitable benefit-sharing, and governance aligning biodiversity stewardship with resilient malaria control.
- Open Access
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 20 (4) , 1365-1372
Quality of Life Among Women with Vulvovaginal Candidiasis in a Tertiary Care Centre in India
Biosciences, Biotechnology Research Asia is an international, open access, peer reviewed research journal covering all aspects of Biosciences and Biotechnology field.
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 20 (4) , 1365-1372
Open AccessQuality of Life Among Women with Vulvovaginal Candidiasis in a Tertiary Care Centre in India
Biosciences, Biotechnology Research Asia is an international, open access, peer reviewed research journal covering all aspects of Biosciences and Biotechnology field.